Pharmacokinetic characteristics of formulated alendronate transdermal delivery systems in rats and humans

Drug Delivery

Volumn 17, Issue 4, 2010, Pages 249-254

  Choi, Ahyoung ^a   Gang, Hyesil ^a   Whang, Jiae ^a   Gwak, Hyesun ^a  

^a Ewha Womans University   (South Korea)

Author keywords

Alendronate; Humans; Oral administration; Pharmacokinetic characteristics; Rats; Transdermal delivery system

Indexed keywords

ALENDRONIC ACID; OCTANOIC ACID; PROPYLENE GLYCOL;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, CUTANEOUS; ALENDRONATE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SKIN ABSORPTION;

EID: 77951445382     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717541003680999     Document Type: Article

References (22)

1. Adami, S., Bolzicco, G.P., Rizzo, A.E., Salvagno, G., Bertoldo, F., Rossini, M., Suppi, R., Lo Cascio V., (1987). The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone Miner. 2:395-404.
2. Ansel, H.C., Popovich, N.G., Allen, L.V. (1995). Pharmaceutical dosage forms and drug delivery systems. Malvern, USA: Williams & Wilkins, pp 357-372
3. Beek, E.R., Cohen, L.H., Leroy, I.M., Ebetino, F.H., Lowik, C.W.G.M., Papapoulos, S.E. (2003). Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonate. Bone. 33:805-811
4. Bickerstaff, D.R., O'Doherty, D.P., McCloskey, E.V., Hamdy, N.A.T., Mian, M., Kanis, J.A. (1991). Effect of amino-butylidene diphosphonate in hypercalcemia due to malignancy. Bone. 17:17-20.
5. Bone, H.G., Adami, S., Rizzoli, R., Favus, M., Ross, P.D., Santota, A., Prahalada, S., Daifotis, A., Orloff, J., Yates, J. (2000). Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther. 22:15-28.
6. Bronaugh, R.L., Stewart, R.F., Congdon, E.R. (1982). Methods for in vitro percutaneous absorption studies. II. Animal models for human skin. Toxicol Appl Pharmacol. 62:481-488
7. Cho, Y.A., Gwak, H.S. (2004). Transdermal delivery of ketorolac tromethamine: effects of vehicles and penetration enhancers. Drug Dev Ind Pharm. 30:557-564
8. Choi, A.Y., Gang, H.S., Chun, I.K., Gwak, H.S. (2008). The effects of fatty acids in propylene glycol on the percutaneous absorption of alendronate across the excised hairless mouse skin. Int J Pharm. 357:126-131
9. Gur, A., Colpan, L., Cevik, R., Nas, K., Sarac, A.J. (2005). Comparison of zinc excretion and biochemical markers of bone remodeling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis. Clin Biochem. 38:66-72.
10. Gwak, H.S., Chun, I.K. (2002). Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. Int J Pharm. 236:57-64.
11. Im, G.I., Qureshi, S.A., Kenney, J., Rubash, H.E., Shanbhag, A.S. (2004). Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 25:4105-4115
12. Lacy, C.F., Amstrong, L.L., Goldman, M.P., Lance, L.L. (2007). Drug information handbook. Hudson, USA: Lexi-comp, pp 63-64
13. Lin, J.H., Russell, G., Gertz, B. (1999). Pharmacokinetics of alendronate: an overview. Int J Clin Pract Suppl. 101:18-26.
14. Nussbaum, S.R., Warrel, R.P., Rude, R., Glusman, J., Bilezikion, J.P., Stewart, A.F., Stepanavage, M., Sacco, J.F., Averbuch, S.D., Gertz, B.J. (1993). Dose-response study of alendronate sodium for the treatment of cancer associated hypercalcemia. J Clin Oncol. 11:1618-1623
15. O'Doherty, D.P., Bicherstaff, D.R., McCloskey, E.V., Hamdy, N.A.T., Beneton, M.N.C., Harris, S., Mian, M., Kanis, JA. (1990). Treatment of Paget's disease of bone with amino-hydroxybutylidene bisphosphonate. J Bone Miner Res. 5:483-491
16. Ponec, M., Haverkort, M., Soei, Y.L., Kempenaar, J., Bodde, H.E. (1990a). Use of human keratinocyte and fibroblast cultures for toxicity studies of topically applied compounds. J Pharm Sci. 79:312-316
17. Ponec, M., Haverkort, M., Soei, Y.L., Kempenaar, J., Brussee, H., Bodde, H.E. (1990b). Toxicity screening of N-alkylazacycloheptan-2-one derivatives in cultured human skin cells: structure-toxicity relationships. J Pharm Sci. 78:738-741
18. Ptáček, P., Klima, J., Macek, J. (2002). Determination of alendronate in human urine as 9-fluorenylmethyl derivative by high-performance liquid chromatography. J Chromatogr B. 767:111-116 (Pubitemid 34142342)
19. Rizzoli, R., Buchs, B., Bonjour, J.P. (1992). Effect of a single infusion of alendronate in malignant hypercalcemia: dose dependency and comparison with clodronate. Int J Cancer. 50:706-712
20. Sato, M., Grasser, W. (1990). Effect of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res. 5:31-40.
21. Schenk, R., Eggi, D.P., Fleisch, D.P., Rosini, S. (1986). Quantitative morphometric evaluation of the inhibitory activity of new amino-bisphosphonates on bone resorption in the rat. Calcif Tissue Int. 38:342-349
22. Traul, K.A., Driedger, A., Ingle, D.L., Nakhasi, D. (2000). Review of the toxicologic properties of medium-chain triglycerides. Food Chem Toxicol. 38:79-98.